SYRE Stock Forecast & Price Target

Spyre Therapeutics is viewed positively because its three in-house antibodies targeting α4β7, TL1A, and IL-23 create a rare, fully integrated combination platform with clear additive-efficacy potential in IBD and beyond. Recent external data from TARGET-CD and tulisokibart in HS strengthen the case that combining mechanisms can lift endoscopic and clinical outcomes without an obvious safety penalty, while Spyre’s YTE half-life extension and coformulation design support more convenient Q3M-Q6M dosing. The company also has multiple upcoming catalysts, including SKYLINE Part B data in 2027 and SPY072 readouts in 4Q26, with 300 patients in TARGET-CD and ~680 in SKYLINE underscoring meaningful clinical scale.

Spyre Therapeutics is facing a fundamentally fragile outlook because its lead programs still depend on regulatory pathways that may demand additional data, longer studies, or stricter approval requirements, any of which could slow or derail commercialization. Its market opportunity is also uncertain since failure to secure labels with the right features could weaken adoption, while competitor updates may pressure sentiment and limit relative upside. Financially, the company will need access to capital markets to fund development and commercialization, and an inability to raise sufficient capital could impair its ability to advance the pipeline.